

EXTENDED DURATION OF IMMUNITY IN A NEW LIVE COCCIDIOSIS VACCINE (EVALON®) FOR BREEDERS AND LAYERS WITH THE USE OF AN ADJUVANTED SOLVENT (HIPRAMUNE® T)

Authors:

Bech G.¹, Ros M.¹, Sitjà M.¹, March R.¹ and Pagès M.^{1*}

***Corresponding author (marc.pages@hipra.com)**

¹HIPRA SCIENTIFIC S.L.U., Amer (Girona), Spain



**The Reference
in Prevention
for Animal Health**


Introduction

- Duration of immunity of Evalon® was studied under laboratory conditions in facilities that impaired the introduction of external *Eimeria* oocysts and that do not favour reinfections. The DOI was evaluated during 60 weeks.
- At 14, 28, 40 and 60 weeks post-vaccination a group of vaccinated and control birds were inoculated with separate *Eimeria* challenges using heterologous reference challenge strains;

<i>Eimeria</i> species	Strain	Dose (esp. ooc/bird)
<i>E.acervulina</i>	Houghton	500,000
<i>E.brunetti</i>	Houghton	50,000
<i>E.maxima</i>	Weybridge	100,000
<i>E.necatrix</i>	Houghton	50,000
<i>E.tenella</i>	Houghton	50,000

Materials and method


- The live attenuated vaccine Evalon® (*E.acervulina* 003, *E.brunetti* 034, *E.maxima* 013, *E.necatrix* 033 and *E.tenella* 004) was applied via coarse-spray together with the adjuvanted solvent Hipramune® T to 1-day-old chicks. A control group was inoculated with PBS.
- Parameters studied included; clinical signs, faeces aspect, mortality, OPG from fresh and litter faeces (see below), weight evolution, lesion scoring post-challenge, elimination of oocysts post-challenge.



Results Lesion Scoring post-challenge

Treatment

CONTROL INFECTED
EVALON + HIPRAMUNE-T



* $p < 0.05$
** $p < 0.01$
*** $p < 0.001$



Conclusion/ Discussion

- For all the challenges performed, vaccinated groups showed a reduction in lesion scores, oocyst excretion and clinical signs compared to control groups. Weight evolution post-challenge was not affected in vaccinated animals.
- The duration of immunity of the vaccine Evalon® for all *Eimeria* species included in the vaccine was confirmed to be until the end of the production cycle (60 weeks).
- It is hypothesized that this extended duration of immunity in conditions that do not favour reinfections is due to the coadministration of Evalon® with the adjuvanted solvent Hipramune® T.

